Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT00984542 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators